# Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia

> **NCT00702754** · PHASE4 · COMPLETED · sponsor: **Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC** · enrollment: 502 (actual)

## Conditions studied

- Cervical Dystonia

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type B

## Key facts

- **NCT ID:** NCT00702754
- **Lead sponsor:** Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2008-05
- **Final completion:** 2008-09
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702754, "Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00702754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*